SRC and pancreatic neoplasm: Given this negative trial in pancreas cancer as well as negative trials involving saracatinib in other malignancies, we do not believe that saracatinib monotherapy for pancreas cancer should be pursued; perhaps, combinational therapies involving a Src inhibitor may prove more beneficial in this patient population.